AI assistant
aTYR PHARMA INC — Director's Dealing 2025
Feb 4, 2025
34337_dirs_2025-02-04_7df5e087-d936-473f-a4fd-1f027561bad6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: aTYR PHARMA INC (ATYR)
CIK: 0001339970
Period of Report: 2025-02-03
Reporting Person: DENYES NANCY (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-03 | Common Stock | M | 2687 | — | Acquired | 27454 | Direct |
| 2025-02-04 | Common Stock | S | 899 | $3.78 | Disposed | 26555 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-03 | Restricted Stock Unit | $ | M | 2687 | Disposed | Common Stock (2687) | Direct |
Footnotes
F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: Includes 2,500 shares acquired on November 15, 2024 under the Company's 2015 Employee Purchase Plan.
F4: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F5: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.